Table 11.
Adverse events (AE) | Nitroxoline | Controls | |
---|---|---|---|
Patients (total) | 234 (100%) | 232 (100%) | |
Patients with AEs# | 23 (9.8%) | 18 (7.8%) | |
Adverse events (total) | 33 | 26 | |
Nervous system disorders | Headache | 3 | 4 |
Dizziness | - | 3 | |
Eye disorders | Eyelid swelling | 1 | - |
Cardiac and circulation disorders | Circulation disorder | - | 1 |
Gastrointestinal disorders | Dysgeusia | - | 1 |
Nausea | 9 | 3 | |
Regurgitation | 1 | 1 | |
Gastralgia | 4 | 3 | |
Obstipation | - | 1 | |
Diarrhoea | 5 | - | |
Metabolim and nutrition disorder | Anorexia | 1 | - |
Urinary disorders | Incontinence | 1 | - |
Reproductive system disorders | Colpitis | 1 | 1 |
Fluor vaginalis | 1 | - | |
Tubal tumor | - | 1 | |
Immune system disorders | Allergy | 1* | 1 |
Skin and subcutaneous tissue disorders | Itching | 1 | 1 |
Urticaria | 1 | 1 | |
Herpes labialis | - | 1 | |
General disorders | Intolerance | 1 | - |
Weakness | 1 | - | |
Fever | 1 | - | |
Musculoskeletal, connective tissue and bone disorders | Back pain | - | 1 |
Flank pain | - | 2 | |
Leg pain | - | 1 |
#comparison of nitroxoline vs. controls (logistic regression with random center effect) p = 0.360; *with papules/pustules.